Ani Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ani (US): 13 reconciled FDA prescription therapies (0.5% 2025 to 2030 cliff risk), $128.3M 2024 CMS Part D & Medicaid spend, and $2,543 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies13
2025 to 2030 Patent-Cliff Revenue Exposure0.5%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$128.3M
2024 Medicare Part D Spend$112.0M
2024 Medicaid Spend$16.4M
California HCAI SB 17 FilingsSpecialty launch notice ($2,543 intro WAC)